Investigating circulating tumor cells in cancer patients
Circulating Tumor Cells (CTC) in Cancer
This study is testing blood samples from adult cancer patients to see if circulating tumor cells can help us understand their cancer better and predict how they might do in the future.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 3000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Basel, Switzerland Academic / other |
| Locations | 2 sites (Basel and 1 other locations) |
| Trial ID | NCT04520672 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on the collection and analysis of circulating tumor cells (CTCs) from blood samples of adult cancer patients at various stages of their disease. It aims to understand the biology of CTCs and their clusters, evaluating their potential as biomarkers for cancer progression and overall survival. The study will also explore key signaling networks active in CTCs across different cancer types, providing insights into their role in cancer biology.
Who should consider this trial
Good fit: Ideal candidates include adult patients with a histologically confirmed diagnosis of solid tumors, such as adenocarcinoma or squamous cell carcinoma.
Not a fit: Patients with blood cancers or those who cannot provide written informed consent will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the understanding of cancer progression and improve patient monitoring through the use of CTCs as biomarkers.
How similar studies have performed: Other studies have shown promise in using circulating tumor cells as biomarkers, indicating that this approach has potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult cancer patients * All patients with histology-based proved diagnosis of cancer, all stages and subtypes can be included. Precancerous lesions cannot be included. * All patients with the diagnosis of a solid tumor including adenocarcinoma, squamous cell carcinoma, neuroendocrine carcinoma, sarcoma * Written pathology report must be available. * Written informed consent. Exclusion Criteria: * No written informed consent. * No proved diagnosis of malignancy by pathology report. * Patients with the diagnosis of blood cancer
Where this trial is running
Basel and 1 other locations
- University Hospital Basel — Basel, Switzerland (Recruiting)
- Department Oncology, Haematology & Immuntherapy, Kantonsspital Baselland — Liestal, Switzerland (Recruiting)
Study contacts
- Principal investigator: Marcus Vetter, PD Dr. med. — Kantonsspital Baselland, Liestal
- Study coordinator: Marcus Vetter, PD Dr. med.
- Email: marcus.vetter@ksbl.ch
- Phone: +41 61 925 27 15
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.